ALPHA COGNITION
Company Snapshot
Founded: 2000
Entity Type: Public
Employees: 52
Region: Canada
Headquarter: British Columbia, Canada
Key Geographics: Canada
Corporate Address: 1200 - 750 West Pender Street Vancouver, British Columbia, V6C Canada Tel. +1-604-564-9244 www.alphacognition.com
Company Overview
Alpha Cognition is a pre-commercial stage biopharmaceutical company focused on neurodegenerative diseases, such as AD, amyotrophic lateral sclerosis (ALS), and cognitive impairment with traumatic brain injury. In July 2024, Alpha Cognition received FDA approval for its first product, Zunveyl (benzgalantamine), for the treatment of mild-to-moderate AD. Zunveyl, a new generation acetylcholinesterase inhibitor (AChEI), was previously known as ALPHA-1062 oral tablet formulation. The company expects Zunveyl to be available by prescription starting in the first quarter of 2025.
Company's Business Segments
- Product : ZUNVEYL, Alpha-1062
- Service : Clinical Tests, Research and Development, Others
Applications/End User Industries
- Healthcare
- Biotechnology
- Pharmaceuticals
- Life Sciences
BCC Research Beacon 